Drug Safety Fears May Limit Reimporting and Shape R&D

Published on: 
Pharmaceutical Technology, Pharmaceutical Technology-02-02-2005, Volume 29, Issue 2

Concerns about risky medicines may reduce pressure to expand drug imports while boosting demand for more comparative analyses of therapies.

Related Content:

Quality SystemsRegulatory WatchPharmaceutical Technology-02-02-2005
PTC Therapeutics Gains FDA Approval for AADC Deficiency Gene Therapy
EMA’s CHMP Gives Positive Opinion for Use of Lecanemab in Early Alzheimer’s Disease
J&J’s Balversa Gains MHRA Marketing Authorization as Monotherapy for Bladder Cancer